^
Association details:
| Biomarker: | MCL1 overexpression |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) + INCB59872 (LSD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1134 - The LSD1 inhibitor INCB059872 is a possible therapeutic option for venetoclax-resistant AML
Published date:
03/10/2021
Excerpt:
Next, to test the effects of INCB059872 in a post-venetoclax AML setting, we generated MV4;11 and Molm13 venetoclax resistant cells by culturing them in increasing concentrations of venetoclax. These cells had elevated MCL1 expression and decreased sensitivity to venetoclax in cell proliferation assays.
